This factsheet provides answers to the most frequently asked questions about the Dual Prevention Pill (DPP), including what it is, who might use it, and how it can be rolled out.
Dual Prevention Pill Research Insights & Development of Strategic Themes
This presentation, by M&C Saatchi World Services, AVAC, and partners, highlights learnings from Human-Centered Design Research undertaken in 2022 to understand the values and motivations of potential users and influencers of the Dual Prevention Pill (DPP) in Kenya, South Africa, and Zimbabwe.
Results of 90 Day Tenofovir plus Levonorgestrel Vaginal Ring Trial: The CONRAD 138 Study
This article from PLOS One presents the results of a randomized, placebo controlled phase I trial of the safety, pharmacokinetics, pharmacodynamics, and acceptability of a 90 day tenofovir plus levonorgestrel vaginal ring used continuously or cyclically in women to prevent both pregnancy and HIV.
DPP Audience & Provider Insights for the DPP Research and Marketing Plan: Phase 1 Research Findings
This report, by M&C Saatchi World Services, AVAC, and partners, highlights learnings from Human-Centered Design Research undertaken in 2022 to understand the values and motivations of potential users and influencers of the Dual Prevention Pill (DPP) in Kenya, South Africa, and Zimbabwe.
Private sector delivery opportunities for the DPP: Lessons from FP for the introduction of MPTs
With anticipated rollout of the DPP just two years away, planning for where to introduce the DPP in the private sector will be critical for ensuring access, but will hinge on where PrEP delivery is already permitted. This webinar shares new findings on private sector opportunities for the DPP in Kenya, South Africa and Zimbabwe.…
Private Sector Delivery Opportunities for the Dual Prevention Pill
This scoping report provides an updated assessment of the private sector delivery options for the dual prevention pill (DPP) in the three countries that are targeted for the initial roll out of the DPP: Kenya, South Africa, and Zimbabwe. The report builds upon previous assessments and analysis that the DPP Consortium have carried out recently,…
Blazing a trail for MPT counseling: Efforts to develop recommendations for the Dual Prevention Pill and reconcile inconsistent guidance for delivering PrEP and oral contraception
This poster from AIDS 2022 describes a process for future efforts to develop appropriate counseling guidance for Multipurpose Technologies, based on learnings from the Dual Prevention Pill and using missed pills as an illustrative example.
How Market Preparation for the Dual Prevention Pill is Reimagining Prevention Programs for a Future with MPTs
This slide deck presentation from AIDS 2022 describes how prevention programs can prepare for multipurpose prevention technology (MPTs) such as the Dual Prevention Pill, which combines protection against pregnancy and HIV, and offers marketing insights. The session also presents recommendations for provider counseling on a combined product. Watch the full session from AIDS 2022 here.
Dual Prevention Pill Desk Review Insights
This desk review by M&C Saatchi collates existing data and insights related to uptake and adherence to HIV prevention, contraceptive, and multi-purpose technology pill products; confirms and identifies gaps in the existing knowledge base; and prompts discussions around key learning questions that need to be addressed to develop a robust and effective marketing and demand…
Review of Effective Marketing and Demand Creation Strategies in HIV Prevention and Family Planning that May Inform Demand-Side Thinking for the Dual Prevention Pill
This scoping review aims to document effective and sustainable demand creation strategies used in HIV prevention and Family Planning interventions, how they may be adapted for the Dual Prevention Pill (DPP), and explores what could be done differently for the DPP.